Skip to Content

'
Gautam Borthakur, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
Department of Leukemia, Division of Cancer Medicine
1515 Holcombe Blvd.
Unit Number: 428
Houston, TX 77030
Phone: 713-563-1586
Fax: 713-792-7885
Email: gborthak@mdanderson.org

Education & Training

Degree-Granting Education

1984 Assam Medical College, Dibrugarh, Assam, India, MBBS, Medicine
1979 Cotton College, Guwahati University, Assam, Assam, India, BS, Biology

Postgraduate Training

7/2004-3/2005 Clinical Fellowship, Leukemia, The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX, Dr. Jorge Cortes
3/2001-6/2004 Clinical Fellowship, Hematology-Oncology, The University of Texas Health Science Center Houston and The University of Texas MD Anderson Cancer Center, Houston, TX, Dr. K. K. Wu
7/1993-6/1996 Clinical Residency, Internal Medicine, The Brooklyn Hospital Center, Brooklyn, NY, Dr. E. Lazar
7/1987-6/1990 Clinical Residency, Pathology, Post-Graduate Institute of Medical Education and Research, Chandigarh, India, Dr. B.N. Datta
9/1985-2/1987 House Officer, Internal Medicine, RML Hospital and GB Pant Hospital, New Delhi, India, Dr. P. Nigam
1/1985-8/1985 Clinical Internship, Medicine, Assam Medical College, Dibrugarh, Assam, India

Board Certifications

2005 American Board of Internal Medicine--Medical Oncology
2004 American Board of Internal Medicine-Hematology
1996 American Board of Internal Medicine
1990 National Academy of Medical Sciences (India)-Patho

Experience/Service

Academic Appointments

Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 4/2005-8/2012

Institutional Committee Activities

Member, Clinical Research Committee 4, 9/2007-8/2010

Honors and Awards

2008-2011 2008 ASCO Cancer Foundation Career Development Award, American Society of Clinical Oncology

Professional Memberships

American Association for Cancer Research
Member, 2006-present
American Society of Clinical Oncology
Member, 2001-present
American Society of Hematology
Member, 2001-present
Harris County Medical Society, TX
Member, 2007-present
Texas Medical Society, TX
Member, 2007-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Kadia TM, Borthakur G, Garcia-Manero G, Faderl S, Jabbour E, Estrov Z, York S, Huang X, Pierce S, Brandt M, Koller C, Kantarjian HM, Ravandi F. Final results of the phase II study of rabbit anti-thymocyte globulin, cyclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol 157(3):312-20, 5/2012. e-Pub 2/2012. PMID: 22360602.
2. Eghtedar A, Borthakur G, Ravandi F, Jabbour E, Cortes J, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia. Am J Hematol 87(3):317-8, 3/2012. e-Pub 1/2012. PMID: 22228403.
3. Dimicoli S, Jabbour E, Borthakur G, Kadia T, Estrov Z, Yang H, Kelly M, Pierce S, Kantarjian H, Garcia-Manero G. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol 87(1):127-9, 1/2012. e-Pub 11/2011. PMID: 22072492.
4. Quintás-Cardama A, Kantarjian H, O'Brien S, Jabbour E, Borthakur G, Ravandi F, Verstovsek S, Shan J, Cortes J. Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. Haematologica 96(6):918-24, 6/2011. e-Pub 2/2011. PMCID: PMC3105655.
5. Santos FP, Jones D, Qiao W, Cortes JE, Ravandi F, Estey EE, Verma D, Kantarjian H, Borthakur G. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer 117(10):2145-55, 5/2011. e-Pub 11/2010. PMCID: PMC3191228.
6. Santos FP, Alvarado Y, Kantarjian H, Verma D, O'Brien S, Mattiuzzi G, Ravandi F, Borthakur G, Cortes J. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer 117(5):982-91, 3/2011. e-Pub 10/2010. PMCID: PMC3039008.
7. Faderl S, Thomas DA, O'Brien S, Ravandi F, Garcia-Manero G, Borthakur G, Ferrajoli A, Verstovsek S, Ayoubi M, Rytting M, Feliu J, Kantarjian HM. Augmented Hyper-CVAD Based on Dose-Intensified Vincristine, Dexamethasone, and Asparaginase in Adult Acute Lymphoblastic Leukemia Salvage Therapy. Clin Lymphoma Myeloma Leuk 11(1):54-9, 2/2011. e-Pub 8/2011. PMCID: PMC3191228.
8. Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-Manero G, Wierda W, Ravandi F, Borthakur G, Rios MB, Cortes J. Predictive factors for outcome and response in patients treated with second generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase post imatinib failure. Blood 117(6):1822-7, 2/2011. e-Pub 10/2010. PMCID: PMC3039008.
9. Al-Kali A, Kantarjian H, Shan J, Bassett R, Quintás-Cardama A, Borthakur G, Jabbour E, Verstovsek S, O'Brien S, Cortes J. Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer 117(2):327-35, 1/2011. e-Pub 9/2010. PMCID: PMC3012766.
10. Borthakur G, Kantarjian H, Ravandi F, Zhang W, Konopleva M, Wright JJ, Faderl S, Verstovsek S, Mathews S, Andreeff M, Cortes JE. Phase 1 Study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 96(1):62-8, 1/2011. e-Pub 10/2010. PMCID: PMC3012766.
11. Tong WG, Kantarjian H, O'Brien S, Faderl S, Ravandi F, Borthakur G, Shan J, Pierce S, Rios MB, Cortes J. Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. Cancer 116(13):3152-9, 7/2010. PMID: 20564631.
12. Samudio IJ, Duvvuri S, Clise-Dwyer K, Watt JC, Mak D, Kantarjian H, Yang D, Ruvolo V, Borthakur G. Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells. Leuk Lymphoma 51(5):911-9, 5/2010. PMCID: PMC3012766.
13. Jones D, Yao H, Romans A, Dando C, Pierce S, Borthakur G, Hamilton A, Bueso-Ramos C, Ravandi F, Garcia-Manero G, Kantarjian H. Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias. Genes Chromosomes Cancer 49(2):182-91, 2/2010. PMCID: PMC2815702.
14. Al Ameri A, Koller C, Kantarjian H, Ravandi F, Verstovsek S, Borthakur G, Pierce S, Mattiuzzi G. Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer 116(1):93-7, 1/2010. e-Pub 10/2009. PMCID: PMC2815702.
15. Cortes JE, Jones D, O'Brien S, Jabbour E, Konopleva M, Ferrajoli A, Kadia T, Borthakur G, Stigliano D, Shan J, Kantarjian H. Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase. J Clin Oncol 28(3):392-7, 1/2010. e-Pub 12/2009. PMCID: PMC2815701.
16. Borthakur G, Huang X, Kantarjian H, Faderl S, Ravandi F, Ferrajoli A, Torma R, Morris G, Berry D, Issa JP. Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma 51(1):73-8, 1/2010. PMCID: PMC2876330.
17. Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C, Borthakur G, Walker B, Zhao W, Shan J, Kantarjian H. Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia. J Clin Oncol 28(3):398-404, 1/2010. e-Pub 12/2009. PMCID: PMC2815702.
18. Bryan J, Borthakur G. Role of rituximab in first-line treatment of chronic lymphocytic leukemia. Ther Clin Risk Manag 7:1-11, 2010. e-Pub 12/2010. PMCID: PMC3039008.
19. Santos FP, Faderl S, Garcia-Manero G, Koller C, Beran M, O'Brien S, Pierce S, Freireich EJ, Huang X, Borthakur G, Bueso-Ramos C, de Lima M, Keating M, Cortes J, Kantarjian H, Ravandi F. Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia 23(12):2275-80, 12/2009. e-Pub 9/2009. PMID: 19741728.
20. Ravandi F, Issa JP, Garcia-Manero G, O'Brien S, Pierce S, Shan J, Borthakur G, Verstovsek S, Faderl S, Cortes J, Kantarjian H. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer 115(24):5746-51, 12/2009. e-Pub 9/2009. PMCID: PMC2794953.
21. Quintás-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, Richie MA, Borthakur G, Konopleva M, Cortes J, Verstovsek S. Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera. J Clin Oncol 27(32):5418-24, 11/2009. e-Pub 10/2009. PMID: 19826111.
22. Kantarjian H, O'Brien S, Ravandi F, Borthakur G, Faderl S, Bueso-Ramos C, Abruzzo L, Pierce S, Shan J, Issa JP, Garcia-Manero G. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS? Cancer 115(22):5202-9, 11/2009. e-Pub 8/2009. PMCID: PMC2783477.
23. Sampat K, Kantarjian H, Borthakur G. Clofarabine: emerging role in leukemias. Expert Opin Investig Drugs 18(10):1559-64, 10/2009. PMCID: PMC2794953.
24. Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW, Brandwein J, Xu W, Mak DH, LaCasse E, Jacob C, Morris SJ, Jolivet J, Andreeff M. Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid Leukemia. J Clin Oncol 27(28):4741-6, 10/2009. e-Pub 8/2009. PMCID: PMC2783477.
25. Verma D, Kantarjian HM, Jones D, Luthra R, Borthakur G, Verstovsek S, Rios MB, Cortes J. Chronic myeloid leukemia (CML) with P190BCR-ABL - analysis of characteristics, outcomes and prognostic significance. Blood 114(11):2232-5, 9/2009. e-Pub 6/2009. PMID: 19531657.
26. Quintás-Cardama A, De Souza Santos FP, Kantarjian H, O'Brien S, Faderl S, Awais A, Borthakur G, Cortes J. Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer 115(17):3935-43, 9/2009. e-Pub 6/2009. PMID: 19517473.
27. Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG, Cortes J. Long-term outcome of patients with chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 114(10):2037-43, 9/2009. e-Pub 6/2009. PMID: 19567878.
28. Alvarado Y, Kantarjian H, O'Brien S, Faderl S, Borthakur G, Burger J, Wierda W, Garcia-Manero G, Shan J, Cortes J. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 115(16):3709-18, 8/2009. PMID: 19517462.
29. Quintás-Cardama A, Cortes JE, O'Brien S, Ravandi F, Borthakur G, Liu D, Bleickardt E, Chen TT, Kantarjian HM. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer 115(13):2912-21, 7/2009. e-Pub 4/2009. PMID: 19402171.
30. Garg R, Faderl S, Garcia-Manero G, Cortes J, Koller C, Huang X, York S, Pierce S, Brandt M, Beran M, Borthakur G, Kantarjian H, Ravandi F. Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia 23(7):1297-302, 7/2009. e-Pub 2/2009. PMID: 19242494.
31. Borthakur G, Lin E, Jain N, Estey EE, Cortes JE, O'Brien S, Faderl S, Ravandi F, Pierce S, Kantarjian H. Survival is poorer in patients with secondary core binding factor acute myelogenous leukemia compared with de novo core binding factor leukemia. Cancer 115(14):3217-21, 7/2009. e-Pub 5/2009. PMCID: PMC2783477.
32. Quintás-Cardama A, Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D, Kornblau S, O'Brien S, Cortes J. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myelogenous leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 113(25):6315-21, 6/2009. e-Pub 4/2009. PMID: 19369233.
33. Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J. Failure to achieve a complete hematologic response at the time of achievement of a major cytogenetic response with second generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood 113(21):5058-63, 5/2009. e-Pub 3/2009. PMID: 19282457.
34. Schimmer AD, O'Brien S, Kantarjian H, Brandwein J, Cheson BD, Minden MD, Yee K, Ravandi F, Giles F, Schuh A, Gupta V, Andreeff M, Koller C, Chang H, Kamel-Reid S, Berger M, Viallet J, Borthakur G. A phase I study of the pan Bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 14(24):8295-301, 12/2008. PMCID: PMC2783477.
35. O'Brien S, Thomas D, Ravandi F, Faderl S, Cortes J, Borthakur G, Pierce S, Garcia-Manero G, Kantarjian HM. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 113(11):3186-91, 12/2008. PMID: 18846563.
36. Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S, Brandt M, Estey E. Randomized Comparison of Cooked and Noncooked Diets in Patients Undergoing Remission Induction Therapy for Acute Myeloid Leukemia. J Clin Oncol 26(35):5684-8, 12/2008. PMID: 18955453.
37. Borthakur G, Kantarjian H, Wang X, Plunkett W, Gandhi V, Faderl S, Garcia-Manero G, Ravandi F, Pierce S, Estey E. Treatment of core binding factor acute myelogenous leukemia with fludarabine, cytarabine and granulocyte colony stimulating factor results in improved event-free survival. Cancer 113(11):3181-5, 12/2008. PMCID: PMC2783477.
38. Yanada M, Borthakur G, Garcia-Manero G, Ravandi F, Faderl S, Pierce S, Kantarjian H, Estey E. Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia. Leuk Res 32(10):1505-9, 10/2008. e-Pub 4/2008. PMCID: PMC2783477.
39. Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F, Estrov Z, Borthakur G, Kwari M, Kantarjian HM. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 113(8):1995-8, 10/2008. e-Pub 8/2008. PMCID: PMC2783477.
40. Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as frontline therapy for patients age >= 60 years with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 112(5):1638-45, 9/2008. e-Pub 6/2008. PMCID: PMC2783477.
41. Stock W, Undevia SD, Bivins C, Ravandi F, Odenike O, Faderl S, Rich E, Borthakur G, Godley L, Verstovsek S, Artz A, Wierda W, Larson RA, Zhang Y, Cortes J, Ratain MJ, Giles FJ. A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs 26(4):331-8, 8/2008. e-Pub 4/2008. PMID: 18425419.
42. Tam CS, Kantarjian H, Garcia-Manero G, Borthakur G, O'Brien S, Ravandi F, Shan J, Cortes J. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 112(3):516-518, 8/2008. e-Pub 5/2008. PMID: 18492956.
43. Badgwell BD, Cormier JN, Wray CJ, Borthakur G, Qiao W, Rolston KV, Pollock RE. Challenges in surgical management of abdominal pain in the neutropenic cancer patient. Ann Surg 248(1):104-109, 7/2008. PMID: 18580213.
44. Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O'Brien S, Ravandi F, Borthakur G, Cortes J. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112(1):53-5, 7/2008. e-Pub 4/2008. PMID: 18403620.
45. Borthakur G, Alvarado Y, Ravandi-Kashani F, Cortes J, Estrov Z, Faderl S, Ivy P, Bueso-Ramos C, Nebiyou Bekele B, Giles F. Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies. Cancer 113(2):360-6, 7/2008. PMCID: PMC2783477.
46. Borthakur G, Ahdab SE, Ravandi F, Faderl S, Ferrajoli A, Newman B, Issa JP, Kantarjian H. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 49(4):690-695, 4/2008. PMID: 18398735.
47. Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, Wierda WG, Pierce S, Estey E, Liu J, Huang X, Kantarjian H. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 22(3):538-543, 3/2008. e-Pub 12/2007. PMID: 18079733.
48. Borthakur G, Lin E, Faderl S, Ferrajoli A, Wierda W, Giles F, Browning ML, Kantarjian H, Keating M, O'Brien S. Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath -1H) based therapies. Cancer 110(11):2478-83, 12/2007. PMID: 17960607.
49. Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey E. Potential cure of acute myeloid leukemia. Cancer 110(12):2756-2760, 12/2007.
50. Quintás-Cardama A, Kantarjian H, O'Brien S, Borthakur G, Bruzzi J, Munden R, Cortes J. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25(25):3908-3914, 9/2007. PMID: 17761974.
51. Borthakur G, Estey AE. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome. Curr Oncol Rep 9(5):373-7, 9/2007. PMCID: PMC2783477.
52. Kantarjian H, O'Brien S, Talpaz M, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Rios MB, Shan J, Giles F, Cortes J. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer 109(8):1556-60, 4/2007. PMID: 17342766.
53. Borthakur G, O'Brien S, Wierda WG, Thomas DA, Cortes JE, Giles FJ, Kantarjian HM, Lerner S, Keating MJ. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab - incidence and predictors. Br J Haematol 136(6):800-5, 3/2007. PMID: 17341265.
54. Aribi A, Borthakur G, Ravandi F, Shan J, Davisson J, Cortes J, Kantarjian H. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer 109(4):713-7, 2/2007. PMID: 17219444.
55. Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D, Wierda W, Ferrajoli A, Kornblau S, Pierce S, Albitar M, Cortes J, Kantarjian H. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 136(4):624-7, 2/2007. PMID: 17223919.
56. Borthakur G, Kantarjian H, Daley G, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Faderl S, Sugrue M, Cortes J. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer 106(2):346-52, 1/2006. PMID: 16342165.
57. Borthakur G, Cortes JE. Imatinib mesylate in the treatment of chronic myelogenous leukemia. Int J Hematol 79(5):411-9, 6/2004. PMID: 15239390.
58. Afshar-Kharghan V, Lopez JA, Gray LA, Padilla A, Borthakur G, Roberts SC, Pruthi RK, Tefferi A. Hemostatic gene polymorphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia. Blood Coagul Fibrinolysis 15(1):21-4, 2004. PMID: 15166939.
59. Borthakur G, Cruz MA, Dong JF, McIntire L, Li F, Lopez JA, Thiagarajan P. Sulfatides inhibit platelet adhesion to von Willebrand factor in flowing blood. J Thromb Haemost 1(6):1288-95, 6/2003. PMID: 12871332.
60. Shrimpton CN, Borthakur G, Larrucea S, Cruz MA, Dong JF, Lopez JA. Localization of the adhesion receptor glycoprotein Ib-IX-V complex to lipid rafts is required for platelet adhesion and activation. J Exp Med 196:1057-66, 10/2002. PMID: 12391017.
Other Articles
1. Jain N, Hubbard J, Vega F, Vidal G, Garcia-Manero G, Borthakur G. Spontaneous remission of acute myeloid leukemia: report of three patients and review of the literature. Clinical Leukemia 2(1):64-67, 2/2008.

Abstracts

1. Borthakur G, Popplewell L, Kirschbaum M, Foran J, Kadia T, Jabbour E, Boyiadzis M, Verma A, Walter R, Wissel P, Xu L, Bauman J, Zhu J, Mazdumar J, Baccus M, Connor J, Cortes J, Kantarjian H. Phase I/II trial of the MEK1/2 inhibitor GSK1120212 in patients with relapsed/refractory myeloid malignancies: Evidence of activity in pts with RAS mutation. J Clin Oncol 29(15) (#6506), 6/2011.
2. Borthakur G, Faderl S, Ravandi F, Padmanabhan S, Stock W, Wu K, Li J, Curt G, Tallman M, Minden M. Clinical, pharmacokinetic (PK), and pharmacodynamic findings from a phase I trial of an Eg5 inhibitor (AZD4877) in patients with refractory acute myeloid leukemia (AML). J Clin Oncol 27(15s):166s (#3580), 5/2009.
3. Borthakur G, Tam C, Kantarjian H, Lin E, Cortes J, O'Brien S, Koller C, Pierce S, Keating M. Chromosome 17 abnormalities are associated with worse overall and relapse free survival in patients with acute myelogenous leukemia and poor-risk cytogenetics. Blood 112(11) (#1501), 11/2008.
4. Borthakur G, Estrov Z, Garcia-Manero G, Williams B, Wathen J, Konopleva M, Burger J, Ferrajoli A, George S, Kantarjian H. Decitabine and gemtuzumab ozogamicin in acute myelogenous leukemia and high-risk myelodysplastic syndrome. Blood 112(11) (#2985), 11/2008.
5. Borthakur G, Faderl S, Verstovsek S, Jones D, Estrov Z, O'Brien S, Bass J, Kantarjian H. Molecular response in core binding factor acute myelogenous leukemia with fludarbine, cytarabine, G-CSF and gemtuzumab ozogamicin. Blood 112(11) (#1937), 11/2008.
6. Borthakur G, Beran M, Liu J, Verma D, Dong X, Rondon G, Champlin R, Kantarjian H, Popat U. Outcomes in patients with chronic myelomonocytic leukemia: analysis of 279 patients. Blood 112(11) (#3235), 11/2008.
7. Borthakur G, deLima M, Kantarjian H, Xiao L, dePadua Silva L, Garcia-Manero G, Giralt S, Ravandi-Kashani F, Pierce S, Champlin R. Stem cell transplantation in remission improves survival in acute myelogenous leukemia associated with FLT3 mutations. Blood 112(11) (#3302), 11/2008.
8. Borthakur G, Kantarjian H, O'Brien S, Jones D, Koller C, Nicaise C, Garcia-Manero G, Ferrajoli A, Cortes J. Efficacy of dasatinib in patients with previously untreated chronic myelogenous leukemia in early chronic phase. J Clin Oncol 26(May 20 suppl) (#7013), 5/2008.
9. Borthakur G, Kantarjian H, O'Brien S, Ravandi F, Koller C, Estrov Z, Torma R, Issa JP. Report of a phase 1/2 study of 5-azacitidine and cytarabine in patients with relapsed, refractory acute myelogenous leukemia. Blood 110(11):277a (#911), 11/2007.
10. Borthakur G, Kantarjian H, Garcia-Manero G, Pierce S, Estey E. Salvage therapy with standard dose cytarabine is appropriate for patients with acute myelogenous leukemia refractory to front-line therapy with hypomethylating agents. Blood 110(11):164b (#4382), 11/2007.
11. Borthakur G, Garcia-Manero G, Faderl S, Estrov Z, Verstovsek S, Hood M, Kantarjian H. Lenalidomide in high-risk myelodysplastic syndrome and acute myelogenous leukemia associated with chromosome 5 abnormalities. Blood 110(11):437a (#1459), 2007.
12. Borthakur G, Ravandi-Kashani F, O'Brien S, Williams B, Giles F. Phase I study of s-trans, trans-farnesylthiosalicyclic acid (FTS), a novel oral Ras inhibitor, in patients with refractory hematologic malignancies. Proc ASCO 25(18S):374s (#7071), 2007.
13. Borthakur G, Ravandi F, O'Brien S, Beran M, Williams B, Goldsweig H, Giles F. Phase I study of S-trans, trans-farnesylthiosalicylic acid, a novel oral Ras inhibitor, in patients with refractory hematologic malignancies. Blood 110(11):478a (#1600), 2007.
14. Borthakur G, Jain N, Kantarjian H, Lin E, Ravandi F, Pierce S, Estey E. Survival is poorer in patients with secondary core binding factor acute myelogenous leukemia compared with de novo core binding factor leukemia. Blood 110(11):840a (#2856), 2007.
15. Borthakur G, O'brien S, Ravandi-Kashani F, Giles F, Schimmer A, Viallet J, Kantarjian H. A phase I trial of the small molecule pan-Bcl-2 family inhibitor obatoclax mesylate (GX15-070) administered by 24 hour infusion every 2 weeks to patients with myeloid malignancies and chronic lymphocytic leukemia. Blood 108(11):750a (#2654), 2006.
16. Borthakur G, Ravandi-Kashani F, Cortes J, Jabbour E, Faderl S, O'brien S, Verstovsek S, Garcia-Manero G, Newman B, Giles F, Issa JP, Kantarjian H. Decitabine induces responses in patients with myelodysplastic syndrome after failure of azacitidine therapy. Blood 108(11):157a (#518), 2006.
17. Borthakur G, O'Brien S, Wierda W, Thomas D, Cortes J, Kantarjian H, Lerner S, Keating M. Immune anemias in patients with chronic lymphocytic leukemia treated with chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab as initial therapy. Proc ASCO 24(18s):361 (#6604), 2006.
18. Borthakur G, Kantarjian H, Wang X, Giles F, Cortes J, Pierce S, Estey E. Induction therapy with fludarabine, ara-C and G-CSF results in improved event free survival in core binding factor leukemia. Blood 108(11):567a (#2004), 2006.
19. Borthakur G, Kantarjian H, Estey E, Verstovsek S, Garcia-Manero G, Cortes J. Study of intravenous homoharringtonine in the treatment of myelodysplastic syndrome. Blood 106(11):305b (#4903), 2005.
20. Borthakur G, Kantarjian H, Verstovsek S, O'brien S, Giles F, Koller C, Rios MB, Cortes JE. Imatinib mesylate therapy for patients with polycythemia vera. Blood 104(11):428a (#1527), 2004.
21. Borthakur G, Matijevic-Aleksic N, Wu KK. CD40L induced COX2 expression in THP-1 cells and HUVEC involves p52/NFKB-2. Blood 102(11):77b (#4012), 2003.
22. Borthakur G, Cortes JE, Estey EH. Incidence and outcome of secondary MDS at MD Anderson Cancer Center 1965-2002. Blood 102(11):331b (#5045), 2003.
23. Borthakur G, Estey EH, Kantarjian H, Koller CA, Giles F, Garcia-Manero G, Cortes J. A randomized trial of interferon-alpha and granulocyte macrophage colony stimulating factor versus interferon and cytarabine versus idarubicin and cytarabine for maintenance therapy in acute myelogenous leukemia, refractory anemia with excess of blasts, refractory anemia with excess of blasts in transformation in first complete remission. Blood 100(11) (#4571), 2002.

Book Chapters

1. Borthakur G, Estey EE. Therapy of acute myelogenous leukemia in adults. In: Cancer Treat Res. 145, 257-71, 2010. ISBN: 20306256.
2. Jabbour E, Borthakur G, Bueso-Ramos C, Kantarjian H, Faderl S. Acute Lymphoblastic Leukemia. In: MD Anderson Manual of Medical Oncology. Ed(s) HM Kantarjian, RA Wolff, CA Koller. McGraw-Hill Medical Publishing Division: United States, 3-17, 2006.
3. Borthakur G, Bueso-Ramos C, O'Brien S. Chronic Lymphocytic Leukemia and Associated Disorders. In: MD Anderson Manual of Medical Oncology. Ed(s) HM Kantarjian, RA Wolff, CA Koller. McGraw-Hill Medical Publishing Division: United States, 39-55, 2006.

Grant & Contract Support

Title: Leukemia SPORE; Project 3: P53 Activation as Novel Therapeutic Strategy for Acute Myelogenous Leukemia
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Hagop Kantarjian, MD
Duration: 9/1/2008 - 8/31/2013
 
Title: Therapy of AML (overall) Project 4:Clinical Trials in AML
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Hagop Kantarjian
Duration: 9/20/2007 - 8/31/2014

Last updated: 7/14/2014